EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

Impact of Dapagliflozin on Cardiometabolic Outcomes After Acute Myocardial Infarction According to Baseline Glycemic Status and Body Mass Index: Subanalyses of the DAPA‐MI Trial

Robert F Storey iD, John Deanfield, Stefan James iD, Ramzi A Ajjan iD, Niclas Eriksson iD, David Erlinge iD, Mark de Belder iD, Chris P Gale iD, Azfar Zaman iD, Robin Hofmann iD, Linda Mellbin iD, Kasper Andersen iD und 7 weitere

Journal of the American Heart Association · 05.08.2025 · 14 (15)

DOI: 10.1161/jaha.124.040327 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of the American Heart Association, erschienen am 05.08.2025. Verfasst von Robert F Storey und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Medicine University of Sheffield United Kingdom. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Blood Glucose, Body Mass Index, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dapagliflozin improved cardiometabolic outcomes following myocardial infarction in patients without prior type‐2 diabetes (T2DM) in the DAPA‐MI (dapagliflozin in patients with myocardial infarction) trial. The effect of glycemic status and body mass index (BMI) post–myocardial infarction requires elucidation.

Methods

Participants with T2DM diagnosis, without baseline hemoglobin A1c , or not receiving any study medication, were excluded. Eligible participants were categorized, according to baseline hemoglobin A1c , as normoglycemic (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsBlood GlucoseBody Mass IndexDiabetes Mellitus, Type 2GlucosidesMyocardial InfarctionPrediabetic StateSodium-Glucose Transporter 2 InhibitorsAgedFemaleHumansMaleMiddle AgedBiomarkersDouble-Blind MethodGlycated HemoglobinTime FactorsTreatment Outcome

Stichwörter der Autor:innen

dapagliflozindiabetesmyocardial infarctionobesityprediabetes

Substanzen

Benzhydryl CompoundsBiomarkersBlood GlucosedapagliflozinGlucosidesGlycated Hemoglobinhemoglobin A1c protein, humanSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Division of Clinical Medicine University of Sheffield United Kingdom.
  • NIHR Sheffield Biomedical Research Centre Sheffield Teaching Hospitals NHS Foundation Trust Sheffield United Kingdom.
  • Institute of Cardiovascular Sciences, University College London London United Kingdom.
  • Uppsala Clinical Research Center, Uppsala University Uppsala Sweden.
  • Department of Medical Sciences, Cardiology Uppsala University Sweden.
  • Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds United Kingdom.

ORCID-Profile: Robert F Storey, Stefan James, Ramzi A Ajjan, Niclas Eriksson, David Erlinge, Mark de Belder, Chris P Gale, Azfar Zaman, Robin Hofmann, Linda Mellbin, Kasper Andersen, Anna Maria Langkilde, Jonas Oldgren, Darren K McGuire

Zitieren

APA

Storey, R. F., Deanfield, J., James, S., Ajjan, R. A., Eriksson, N., Erlinge, D., de Belder, M., Gale, C. P., Zaman, A., Hofmann, R., Mellbin, L., Andersen, K., Jiang, Y., Johansson, P. A., Ridderstråle, W., Langkilde, A. M., Parvaresh Rizi, E., Oldgren, J., & McGuire, D. K. (2025). Impact of Dapagliflozin on Cardiometabolic Outcomes After Acute Myocardial Infarction According to Baseline Glycemic Status and Body Mass Index: Subanalyses of the DAPA‐MI Trial. Journal of the American Heart Association, 14(15). https://doi.org/10.1161/jaha.124.040327

Vancouver

Storey RF, Deanfield J, James S, Ajjan RA, Eriksson N, Erlinge D, et al. Impact of Dapagliflozin on Cardiometabolic Outcomes After Acute Myocardial Infarction According to Baseline Glycemic Status and Body Mass Index: Subanalyses of the DAPA‐MI Trial. Journal of the American Heart Association. 2025;14(15). doi:10.1161/jaha.124.040327

BibTeX
@article{Storey2025,
  author = {Storey, Robert F and Deanfield, John and James, Stefan and Ajjan, Ramzi A and Eriksson, Niclas and Erlinge, David and de Belder, Mark and Gale, Chris P and Zaman, Azfar and Hofmann, Robin and Mellbin, Linda and Andersen, Kasper and Jiang, Yunyun and Johansson, Peter A and Ridderstråle, Wilhelm and Langkilde, Anna Maria and Parvaresh Rizi, Ehsan and Oldgren, Jonas and McGuire, Darren K},
  title = {Impact of Dapagliflozin on Cardiometabolic Outcomes After Acute Myocardial Infarction According to Baseline Glycemic Status and Body Mass Index: Subanalyses of the DAPA‐MI Trial},
  journal = {Journal of the American Heart Association},
  year = {2025},
  volume = {14},
  number = {15},
  doi = {10.1161/jaha.124.040327}
}
Kostenlos starten →